BIOMAT Database Logo BIOMAT Database Logo

Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia. 2010

Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
EA 2216, Université de Bretagne, Brest, France.

BACKGROUND We previously reported that allanxanthone C and macluraxanthone, two xanthones purified from Guttiferae trees, display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic lymphocytic leukemia (CLL) and leukemia B cell lines. RESULTS Here, we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of human CLL, developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant prolongation of their survival as compared to control animals injected with the solvent alone (p = 0.0006 and p = 0.0141, respectively). The same treatment of mice which were not xenografted induced no mortality. CONCLUSIONS These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones, and confirm their potential interest for CLL therapy.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015451 Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. B-Cell Leukemia, Chronic,B-Lymphocytic Leukemia, Chronic,Chronic Lymphocytic Leukemia,Leukemia, B-Cell, Chronic,Leukemia, Lymphocytic, Chronic,Lymphocytic Leukemia, Chronic, B-Cell,Lymphoma, Small Lymphocytic,B-Cell Chronic Lymphocytic Leukemia,B-Cell Malignancy, Low-Grade,Diffuse Well-Differentiated Lymphocytic Lymphoma,Disrupted In B-Cell Malignancy,Leukemia, B Cell, Chronic,Leukemia, Chronic Lymphatic,Leukemia, Chronic Lymphocytic,Leukemia, Chronic Lymphocytic, B-Cell,Leukemia, Lymphoblastic, Chronic,Leukemia, Lymphocytic, Chronic, B Cell,Lymphoblastic Leukemia, Chronic,Lymphocytic Leukemia, Chronic,Lymphocytic Leukemia, Chronic, B Cell,Lymphocytic Lymphoma,Lymphocytic Lymphoma, Diffuse, Well Differentiated,Lymphocytic Lymphoma, Diffuse, Well-Differentiated,Lymphocytic Lymphoma, Well Differentiated,Lymphocytic Lymphoma, Well-Differentiated,Lymphoma, Lymphocytic,Lymphoma, Lymphocytic, Diffuse, Well Differentiated,Lymphoma, Lymphocytic, Diffuse, Well-Differentiated,Lymphoma, Lymphocytic, Well Differentiated,Lymphoma, Lymphocytic, Well-Differentiated,Lymphoma, Lymphoplasmacytoid, CLL,Lymphoma, Small Lymphocytic, Plasmacytoid,Lymphoma, Small-Cell,Lymphoplasmacytoid Lymphoma, CLL,Small-Cell Lymphoma,B Cell Chronic Lymphocytic Leukemia,B Cell Leukemia, Chronic,B Cell Malignancy, Low Grade,B Lymphocytic Leukemia, Chronic,B-Cell Leukemias, Chronic,B-Cell Malignancies, Low-Grade,B-Lymphocytic Leukemias, Chronic,CLL Lymphoplasmacytoid Lymphoma,CLL Lymphoplasmacytoid Lymphomas,Chronic B-Cell Leukemia,Chronic B-Cell Leukemias,Chronic B-Lymphocytic Leukemia,Chronic B-Lymphocytic Leukemias,Chronic Lymphatic Leukemia,Chronic Lymphatic Leukemias,Chronic Lymphoblastic Leukemia,Chronic Lymphoblastic Leukemias,Chronic Lymphocytic Leukemias,Diffuse Well Differentiated Lymphocytic Lymphoma,Disrupted In B Cell Malignancy,Leukemia, Chronic B-Cell,Leukemia, Chronic B-Lymphocytic,Leukemias, Chronic B-Cell,Leukemias, Chronic B-Lymphocytic,Leukemias, Chronic Lymphatic,Leukemias, Chronic Lymphoblastic,Low-Grade B-Cell Malignancies,Low-Grade B-Cell Malignancy,Lymphatic Leukemia, Chronic,Lymphatic Leukemias, Chronic,Lymphoblastic Leukemias, Chronic,Lymphocytic Leukemias, Chronic,Lymphocytic Lymphoma, Small,Lymphocytic Lymphomas,Lymphocytic Lymphomas, Small,Lymphocytic Lymphomas, Well-Differentiated,Lymphoma, CLL Lymphoplasmacytoid,Lymphoma, Small Cell,Lymphoma, Well-Differentiated Lymphocytic,Lymphomas, CLL Lymphoplasmacytoid,Lymphomas, Lymphocytic,Lymphomas, Small Lymphocytic,Lymphomas, Small-Cell,Lymphomas, Well-Differentiated Lymphocytic,Lymphoplasmacytoid Lymphomas, CLL,Malignancies, Low-Grade B-Cell,Malignancy, Low-Grade B-Cell,Small Cell Lymphoma,Small Lymphocytic Lymphoma,Small Lymphocytic Lymphomas,Small-Cell Lymphomas,Well-Differentiated Lymphocytic Lymphoma,Well-Differentiated Lymphocytic Lymphomas
D016513 Mice, SCID Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice. SCID Mice,SCID-hu Mice,Severe Combined Immunodeficient Mice,Immunodeficient Mice, Severe Combined,Mouse, SCID,Mouse, SCID-hu,Mice, SCID-hu,Mouse, SCID hu,SCID Mouse,SCID hu Mice,SCID-hu Mouse
D044004 Xanthones A group of XANTHENES that contain a 9-keto OXYGEN. Xanthone Derivatives,Derivatives, Xanthone
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D023041 Xenograft Model Antitumor Assays In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness. Tumor Xenograft Assay,Xenograft Antitumor Assays,Antitumor Assays, Xenograft Model,Antitumor Assay, Xenograft,Antitumor Assays, Xenograft,Assay, Tumor Xenograft,Assay, Xenograft Antitumor,Assays, Tumor Xenograft,Assays, Xenograft Antitumor,Tumor Xenograft Assays,Xenograft Antitumor Assay,Xenograft Assay, Tumor,Xenograft Assays, Tumor

Related Publications

Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia.
July 2014, Seminars in hematology,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
January 2020, Anti-cancer agents in medicinal chemistry,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Epigenetic alterations in a murine model for chronic lymphocytic leukemia.
November 2009, Cell cycle (Georgetown, Tex.),
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.
August 2009, Proceedings of the National Academy of Sciences of the United States of America,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Rutin inhibits human leukemia tumor growth in a murine xenograft model in vivo.
August 2012, Environmental toxicology,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia.
May 1982, Blood,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Inhibition of human B-cell chronic lymphocytic leukemia by a monoclonal antibody in xenograft models.
February 1994, International journal of cancer,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Chronic lymphocytic leukemia: therapeutic options.
January 1976, International journal of radiation oncology, biology, physics,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Therapeutic Targets in Chronic Lymphocytic Leukemia.
November 2020, Cancers,
Séverine Loisel, and Karine Le Ster, and Michèle Meyer, and Christian Berthou, and Pierre Youinou, and Jean-Pierre Kolb, and Christian Billard
Therapeutic cytapheresis in chronic lymphocytic leukemia.
January 1983, Journal of clinical apheresis,
Copied contents to your clipboard!